ProCE Banner Activity

Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know

Slideset Download

Download these slides from a live meeting series featuring guidance from an oncology endocrinologist and medical oncologist on best practices for biomarker testing in advanced thyroid cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET–altered, NTRK fusion–positive, and BRAF V600E–positive disease.

Released: January 04, 2023



Maria E. Cabanillas

Maria E. Cabanillas, MD

Department of Endocrine Neoplasia and Hormonal Disorders
The University of Texas MD Anderson Cancer Center
Houston, Texas

Lori J. Wirth

Lori J. Wirth, MD

Associate Professor
Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group



American Society for Clinical Pathology

ProCE Banner

Partnered with the American Society for Clinical Pathology.